Why Chemed Corporation (CHE) Stock Rose 4.8% on Oct 28, 2026
What happened
Chemed reported third-quarter earnings on Oct 28 with adjusted diluted EPS of $6.75, beating consensus estimates of $6.44, on revenue of $690.9 million. The beat was driven by improved VITAS hospice operating metrics with reduced Medicare cap exposure and stabilization at Roto-Rooter (segment sales +7.5% to $233.5 million). Jefferies upgraded CHE to Buy and Bank of America raised its price target to $555 from $550. The stock surged +9.08% to $555.34 on above-average volume of 1.59x normal levels.
Chemed's next earnings announcement is scheduled for February 24, 2027; consensus EPS estimate is $7.40. Monitor whether the company can sustain VITAS' Medicare cap reductions and Roto-Rooter's 7.5% segment growth in coming quarters.
Other developments that session
Chemed held Q3 2026 earnings call on October 28, reporting third-quarter financial results.
Frequently asked questions
Why did Chemed Corporation (CHE) stock rise on Oct 28, 2026?
Chemed reported third-quarter earnings on Oct 28 with adjusted diluted EPS of $6.75, beating consensus estimates of $6.44, on revenue of $690.9 million. The beat was driven by improved VITAS hospice operating metrics with reduced Medicare cap exposure and stabilization at Roto-Rooter (segment sales +7.5% to $233.5 million). Jefferies upgraded CHE to Buy and Bank of America raised its price target to $555 from $550. The stock surged +9.08% to $555.34 on above-average volume of 1.59x normal levels.
How much did CHE stock rise on Oct 28, 2026?
CHE rose 4.8% during the Oct 28, 2026 trading session.